Anteris Technologies Ltd has submitted a confidential draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") by its affiliate, Anteris Technologies Global Corp. (“Anteris Global”), relating to the proposed U.S. initial public offering by Anteris Global of its shares of common stock (the “Proposed Offering”).
The number of shares of common stock to be offered and the price range for the Proposed Offering have not been determined. The Proposed Offering is expected to occur after the SEC completes its review process, subject to market and other conditions.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"). This announcement is being issued pursuant to and in accordance with Rule 135 under the Securities Act.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813095659/en/
Investor Relations
Debbie Ormsby
investors@anteristech.com
Anteris Technologies Ltd
+61 1300 550 310 | +61 7 3152 3200
Investor Relations (US)
Malini Chatterjee, Ph.D.
Managing Director
Blueprint Life Science Group
+1 917 330 4269
Source: Anteris Technologies Ltd